[
  {
    "ts": null,
    "headline": "Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance",
    "summary": "Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's results. Click for this VYGR update.",
    "url": "https://finnhub.io/api/news?id=df0472f0d9bbaa3ae1653611aab840d47121551d78f2f5f5d1585eec4d644274",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738256764,
      "headline": "Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance",
      "id": 132501141,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2004780179/image_2004780179.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's results. Click for this VYGR update.",
      "url": "https://finnhub.io/api/news?id=df0472f0d9bbaa3ae1653611aab840d47121551d78f2f5f5d1585eec4d644274"
    }
  }
]